丸美生物
(603983)
| 流通市值：99.61亿 | | | 总市值：99.61亿 |
| 流通股本：4.01亿 | | | 总股本：4.01亿 |
| 报告期 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,459,318,084 | 2,450,380,539.41 | 1,764,646,729.2 | 846,648,701.63 |
| 营业收入 | 3,459,318,084 | 2,450,380,539.41 | 1,764,646,729.2 | 846,648,701.63 |
| 二、营业总成本 | 3,214,916,856.76 | 2,206,220,208.73 | 1,550,885,924.71 | 684,279,945.76 |
| 营业成本 | 889,519,268.27 | 614,706,979.79 | 448,184,341.2 | 202,740,941.83 |
| 税金及附加 | 40,468,775.32 | 28,878,373.64 | 13,465,361.25 | 6,454,631.6 |
| 销售费用 | 2,056,503,826.51 | 1,414,567,358.33 | 999,196,374.25 | 441,717,448.89 |
| 管理费用 | 160,992,386.17 | 101,172,990.99 | 60,753,973.5 | 24,533,886.45 |
| 研发费用 | 85,371,565.84 | 62,788,807.55 | 39,964,788.86 | 15,927,066.39 |
| 财务费用 | -17,938,965.35 | -15,894,301.57 | -10,678,914.35 | -7,094,029.4 |
| 其中:利息费用 | 3,282,855.41 | 2,689,869.53 | 2,656,560.66 | 866,083.3 |
| 其中:利息收入 | 21,696,773.74 | 18,928,874.75 | 13,364,648.6 | 7,992,870.12 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 432,554.85 | 22,698,859.7 | 587,598.74 | 189,317.92 |
| 加:投资收益 | 27,553,438.99 | 16,823,669.04 | 2,783,249.38 | 1,526,876.83 |
| 资产处置收益 | 377,398.06 | 377,398.06 | 377,398.06 | 382,013.03 |
| 资产减值损失(新) | -3,287,597.39 | -1,715,369.91 | -1,349,645.31 | -819,952.73 |
| 信用减值损失(新) | -312,116.8 | 319,316.89 | 228,622.4 | -225,474.27 |
| 其他收益 | 27,446,152.38 | 16,412,852.63 | 12,732,895.09 | 2,562,014.1 |
| 四、营业利润 | 296,611,057.33 | 299,077,057.09 | 229,120,922.85 | 165,983,550.75 |
| 加:营业外收入 | 688,747.35 | 570,962.23 | 383,317.79 | 175,884.7 |
| 减:营业外支出 | 1,568,360.1 | 1,126,541.95 | 651,743.16 | 7,947.65 |
| 五、利润总额 | 295,731,444.58 | 298,521,477.37 | 228,852,497.48 | 166,151,487.8 |
| 减:所得税费用 | 48,988,618.75 | 51,872,160.73 | 54,140,050.44 | 30,953,790.62 |
| 六、净利润 | 246,742,825.83 | 246,649,316.64 | 174,712,447.04 | 135,197,697.18 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 246,742,825.83 | 246,649,316.64 | 174,712,447.04 | 135,197,697.18 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 247,239,140.99 | 243,892,254.22 | 174,410,644.57 | 135,045,089.33 |
| 少数股东损益 | -496,315.16 | 2,757,062.42 | 301,802.47 | 152,607.85 |
| 扣除非经常损益后的净利润 | 231,225,157.4 | 214,069,755.26 | 166,044,031.92 | 134,079,492.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.62 | 0.61 | 0.43 | 0.34 |
| (二)稀释每股收益 | 0.62 | 0.61 | 0.43 | 0.34 |
| 八、其他综合收益 | -22,246.12 | -73,087.1 | -112,116.33 | -59,597.35 |
| 归属于母公司股东的其他综合收益 | -22,246.12 | -73,087.1 | -112,116.33 | -59,597.35 |
| 九、综合收益总额 | 246,720,579.71 | 246,576,229.54 | 174,600,330.71 | 135,138,099.83 |
| 归属于母公司股东的综合收益总额 | 247,216,894.87 | 243,819,167.12 | 174,298,528.24 | 134,985,491.98 |
| 归属于少数股东的综合收益总额 | -496,315.16 | 2,757,062.42 | 301,802.47 | 152,607.85 |
| 公告日期 | 2026-04-01 | 2025-10-31 | 2025-08-23 | 2025-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |